Oxsed, a University of Oxford spinout, will continue to focus on prioritizing test access for low- and middle-income countries following the acquisition.
The company's acquisitions of Thrive Early Detection and Base Genomics are meant to accelerate its development of a liquid biopsy multi-cancer screening test.
The company also acquired DNA methylation analysis firm Base Genomics for $410 million and said it plans to raise $869 million in a direct stock offering.
Cyted, a provider of AI and digital diagnostic technology, said the acquisition of Pathognomics will provide it with an accredited lab and digital pathology technology.
Novacyt said that the acquisition secures important intellectual property for its q16 and q32 rapid-PCR instruments for near-patient testing of COVID-19.
Qiagen has benefited from unexpected tailwinds due to COVID-19 testing and envisions post-pandemic growth with recently acquired NeuMoDx as a key contributor.
The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.
